A classification of drug substances according to their mechanism of action

Pharmazie

Volumn 59, Issue 8, 2004, Pages 579-589

  Imming, P ^a,b   Buss, T ^a   Dailey, L A ^a   Meyer, A ^a   Morck, H ^a   Ramadan, M ^a   Rogosch, T ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; DISULFIRAM; DRUG; DUTASTERIDE; ENTACAPONE; ENZYME; ETHIONAMIDE; EXEMESTANE; FINASTERIDE; HEPARIN; HYDROLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ION CHANNEL; ISONIAZID; LYASE; MESALAZINE; METHOTREXATE; MOCLOBEMIDE; OXIDOREDUCTASE; PARACETAMOL; PHENPROCOUMON; PROGUANIL; PYRAZINAMIDE; THIOURACIL DERIVATIVE; TRANSFERASE; TRANYLCYPROMINE; TRIMETHOPRIM; UNINDEXED DRUG; WARFARIN; ZILEUTON;

CURRICULUM; DRUG CLASSIFICATION; DRUG DNA BINDING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME MECHANISM; PHARMACEUTICS; REVIEW; RIBOSOME; RNA BINDING; STANDARD;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY;

EID: 4143122130     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. th ed., London, 2001.
2. Burgess C, Golden J (2002) IBC Drug Discovery and Technology Conference, CuraGen Corp., Boston (http://www.bio-itworld.com/archive/100902/firstbase.html) .
3. Drews J, Ryser S (1997) The role of innovation in drug development. Nature Biotechnol 15: 1318-1319. See also http://bionlp.stanford.edu/drews. ryser.html.
4. Frantz S (2004) 2003 approvals: a year of innovation and upward trends. Nature Rev Drug Discov 3: 103-106.
5. Gohlke H, Klebe G (2002) Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed Engl 41: 2644-2676.
6. Goldberg NR, Beuming T, Soyer OS, Goldstein RA, Weinstein H, Javitch JA (2003) Probing conformational changes in neurotransmitter transporters: a structural context. Eur J Pharmacol 479: 3-12.
7. Goodnow RA Jr, Guba W, Haap W (2003) Library design practices for success in lead generation with small molecule libraries. Comb Chem High Throughput Screen 6: 649-660.
8. Hendlich M, Bergner A, Gunther J, Klebe G (2003) Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. J Mol Biol 326: 607-620.
9. Hopkins A, Groom C (2002) The druggable genome. Nature Rev Drug Discov 1: 727-730.
10. Hyman SE, Fenton WS (2003) What are the right targets for psychopharmacology? Science 299: 350-351.
11. Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) "Mutschler Arzneimittelwirkungen", 8th ed., Stuttgart.
12. Pharmazeutische Zeitung (2003) Neue Arzneistoffe. www. pharmazeutischezeitung.de.
13. Saier Jr MH (1999) A functional-phylogenetic system for the classification of transport proteins. J Cell Biochem Suppl 32-33: 84-94.
14. Schneider G (2002) Trends in virtual combinatorial library design. Curr Med Chem 9: 2095-2101.
15. Schwabe U (1995) ATC-Code. Bonn.
16. World Health Organization (2002) The Essential Medicines List. http://www.who.int/medicines/rationale.shtml.